ACIU Comptes : Analyse IA AC Immune SA

Accueil

Stock

ACIU

ACIU Financier

AC Immune SA

$2.99

2.04%

$0.06

À la fermeture : Feb 13, 16:00:00 GMT-5

$2.99

Post-Marché: Feb 13, 20:00:00 GMT-5

Aperçu Prévision Gagner Dividendes Comptes financiers

Revenus

État de situation

Flux de trésorerie

Annuel

Trimestriellement

ACIU Revenu

Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenus	4	27	14	3	0	15
Croissance des revenus (H/H)	-90%	93%	367%	--	-100%	-86%
Coût des ventes	--	--	--	--	--	--
Bénéfice brut	--	--	--	--	--	--
Vente, Général et Administration	11	11	10	9	10	11
Recherche et développement	61	62	54	60	62	59
Frais d'exploitation	77	79	68	74	79	76
Autres revenus (charges) non opérationnels	--	--	--	--	0	0
Bénéfice avant impôts	-71	-50	-54	-70	-73	-61
Charge d'impôt sur le revenu	0	0	0	0	0	0
Bénéfice net	-71	-50	-54	-70	-73	-61
Croissance du bénéfice net	82%	-7%	-23%	-4%	20%	-236%
Actions en circulation (diluées)	100.89	99.69	84.69	83.6	75	71.9
Variation des actions (H-H)	0%	18%	1%	11%	4%	1%
EPS (dilué)	-0.71	-0.51	-0.64	-0.85	-0.97	-0.86
Croissance du EPS	75%	-20%	-25%	-12%	13%	-234%
Flux de trésorerie libre	-47	65	-61	-74	-68	-61
Flux de trésorerie libre par action	--	--	--	--	--	--
Marge brute	--	--	--	--	--	--
Marge opérationnelle	-1,825%	-192.59%	-378.57%	-2,333.33%	0%	-406.66%
Marge bénéficiaire	-1,775%	-185.18%	-385.71%	-2,333.33%	0%	-406.66%
Marge du flux de trésorerie libre	-1,175%	240.74%	-435.71%	-2,466.66%	0%	-406.66%
EBITDA	-71	-50	-51	-68	-77	-60
Marge EBITDA	-1,775%	-185.18%	-364.28%	-2,266.66%	0%	-400%
D&A pour le résultat opérationnel	2	2	2	2	2	1
EBIT	-73	-52	-53	-70	-79	-61
Marge EBIT	-1,825%	-192.59%	-378.57%	-2,333.33%	0%	-406.66%
Taux d'imposition effectif	0%	0%	0%	0%	0%	0%

Statistiques clés

Clôture préc.

$2.93

Prix d'ouverture

$2.97

Plage de la journée

$2.93 - $3.03

Plage de 52 semaines

$1.42 - $4

Volume

145.8K

Volume moyen

593.7K

BPA (TTM)

-0.72

Rendement en dividend

Capitalisation boursière

$300.2M

Qu’est-ce que ACIU ?

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.



Fonctionnalités

Copilote IA pour actions et cryptomonnaies

Prédiction des prix

Suivi des collectes de fonds

Thèmes

Comparaison de cryptomonnaies

Ressources